NCT06697847

Brief Summary

The sweet threshold (concentration of sucrose in water) at which healthy participants can detect a sweet flavour will be recorded.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Nov 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 18, 2024

Completed
2 days until next milestone

First Posted

Study publicly available on registry

November 20, 2024

Completed
7 days until next milestone

Study Start

First participant enrolled

November 27, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

March 14, 2025

Completed
Last Updated

November 27, 2024

Status Verified

November 1, 2024

Enrollment Period

2 months

First QC Date

November 18, 2024

Last Update Submit

November 25, 2024

Conditions

Keywords

Taste thresholdsHealthy volunteers

Outcome Measures

Primary Outcomes (1)

  • Sweet taste threshold

    Sweet taste threshold established by applying varying concentrations of sucrose solution to the tongue and assessing whether a sweet taste can be detected by the participant. The sweet threshold is the minimum concentration at which a participant can reliably detect the sweet flavour.

    From enrolment to a final taste test 6 weeks later

Secondary Outcomes (3)

  • Score on Becks Depression Inventory

    From enrolment to a final questionnaire 6 weeks later

  • Score on Patient Health Questionnaire 9

    From enrolment to a final questionnaire 6 weeks later

  • Score on Generalised Anxiety Disorder scale 7

    From enrolment to a final questionnaire 6 weeks later

Study Arms (1)

Healthy volunteers

Adults with no mood disorder and who have not been diagnosed with or had treatment for a mood disorder in the last 6 months.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adults without mood questionnaires recruited by word of mouth and posters in retail establishments in England and Wales

You may qualify if:

  • Male and female adults of 18 years old and over;
  • Participants without a diagnosis of major depressive disorder (MDD) / anxiety disorder;
  • Participants not taking an antidepressant during the preceding 6 months
  • Not suffering from significant other mental or physical illness, such as confirmed psychosis, end of life care, or any other condition assessed as significant by the Site Investigator;
  • Willing and able to comply with all study-related procedures;
  • Not having COVID 19 or continuing effects of COVID 19 including altered sense of taste;
  • Understands the study requirements and the treatment procedures and is able to provide written informed consent.

You may not qualify if:

  • Taking antidepressant medication currently or during the previous 6 months;
  • Known or suspected hypersensitivity or intolerance to any taste testing solutions, or any of their excipients;
  • A history or presence of neurological or confounding psychiatric conditions (such as stroke, traumatic brain injury, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, or schizophrenia);
  • Patients with a diagnosis of chronic pain;
  • Pregnancy or possibility pregnancy, or breastfeeding;
  • Participants using supplements containing psychoactive herbs (for example St Johns Wort or 5-HTP (5-Hydroxytryptophan, also known as oxitriptan);
  • Participants regularly using psychoactive stimulants (for example MDMA);
  • Participants unable or unwilling to comply with study procedures.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Westbury Lodge, Westbury Park

Bristol, City Of Bristol, BS6 7JE, United Kingdom

RECRUITING

Central Study Contacts

David Adams S Chief Investigator, MBChB

CONTACT

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
CROSS SECTIONAL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 18, 2024

First Posted

November 20, 2024

Study Start

November 27, 2024

Primary Completion

January 31, 2025

Study Completion

March 14, 2025

Last Updated

November 27, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Data collected contains sensitive information and even when anonymised contains commercially sensitive information

Locations